Table 1.
List of clinical trials including uLMS patients.
| Identifier | Target | Interventions | Notes, References |
|---|---|---|---|
| NCT01637961 | AURKA | Alisertib | Phase II; uLMS; completed, no response |
| NCT00378911 | VEGFR1/2/3, PDGFRa/b, c-KIT, RET, GCSFR, FLT-3 | Sunitinib malate | Phase II; uLMS; completed, but no results reported |
| NCT02428192 | CTLA4, PD-1 | Ipilimumab and Nivolumab | Phase II; uLMS; active, no response [67] |
| NCT03880019 | PARP | Olaparib and Temozolomide | Phase II; uLMS; active, no results [67] |
| NCT01012297 | VEGF | Bevacizumab | Phase III; no response [68] |
| NCT02203760 | VEGFR1/2/3, PDGFRa/b, c-KIT | Pazopanib + Gemcitabine | Phase II; metastatic uLMS or UCS; recruiting |
| NCT02601209 | VEGFR1/2/3, PDGFRa/b, c-KIT, mTORC1/mTORC2 | Pazopanib or Sapanisertib | Phase I/II; unresectable LMS and STS; slight benefit with pazopanib [69] |
| NCT04200443 | VEGFR2, c-Met, AXL, RET | Cabozantinib | Phase II; unresectable LMS and STS; recruiting |
| NCT00659360 | Src, Lck, Fyn, Lyn, c-Yes, Blk, Abl EGFRmut | Saracatinib | Phase II; LMS, STS, and uterine sarcoma (US); no response |
| NCT00245102 | VEGFR1/2/3, PDGFRb, RAF-1, BRAF (wt and mut), c-KIT, FLT-3 | Sorafenib tosylate | Phase II; LMS, STS, and US; no response |
| NCT00390234 | VEGF-Trap | Ziv-Aflibercept | Phase II; uLMS, UCS, and US; no response |
| NCT01442662 | VEGFR1/2/3, PDGFRa/b, c-KIT | Pazopanib + Gemcitabine | Phase II; second-line LMS; no response [70] |
| NCT00474994 | VEGFR1/2/3, PDGFRa/b, c-KIT, FLT-3, CSF1R, RET | Sunitinib malate | Phase II; metastatic/recurrent sarcomas; SD best response [71] |
| NCT00526149 | PLK1/2/3, BRD4 | BI-2536 | Phase II; metastatic/recurrent solid tumours; no response [72] |
| NCT00006357 | PDGFR, c-KIT, Abl | Imatinib mesylate | Phase I/II; recurrent/refractor STS; no response [73] |
| NCT00053794 | AKT | Perifosine | Phase II; metastatic STS; no response [74] |